Boehringer
Ingelheim has announced plans to expand its stroke awareness campaign «1
Million - 1 Mission» with a new phase this year.
The
initiative - which is sponsored by Boehringer Ingelheim in collaboration with
AntiCoagulation Europe, the Atrial Fibrillation Association, the Stroke
Alliance for Europe and the World Heart Federation - is set to enter a new
phase that will highlight the link between atrial fibrillation (AF) and stroke.
Community-based
action will be at the core of this new phase, with 1 Mission 1 Million set to
support projects around the world, while offering a platform for patients and
carers to share their stories.
It is
thought that around three million people worldwide suffer from an AF-related
stroke every year.
Trudie
Lobban, founder and chief executive officer of the Atrial Fibrillation
Association, said: "There will be many ways people can get involved and
come together to ensure AF-related stroke prevention is recognised and managed
effectively across the world."
This comes
in the same week that Boehringer Ingelheim reported positive data from a new
safety study of its successful AF therapy Pradaxa.